Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults.

IF 8.8 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Zekeriya Aktürk, Alexander Hapfelmeier, Alexey Fomenko, Daniel Dümmler, Stefanie Eck, Michaela Olm, Jan Gehrmann, Victoria von Schrottenberg, Rahel Rehder, Sarah Dawson, Bernd Löwe, Gerta Rücker, Antonius Schneider, Klaus Linde
{"title":"Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults.","authors":"Zekeriya Aktürk, Alexander Hapfelmeier, Alexey Fomenko, Daniel Dümmler, Stefanie Eck, Michaela Olm, Jan Gehrmann, Victoria von Schrottenberg, Rahel Rehder, Sarah Dawson, Bernd Löwe, Gerta Rücker, Antonius Schneider, Klaus Linde","doi":"10.1002/14651858.CD015455","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anxiety disorders often remain undetected and can cause substantial burden. Amongst the many anxiety screening tools, the 7-item Generalized Anxiety Disorder (GAD-7) scale and its short version, the 2-item Generalized Anxiety Disorder (GAD-2) scale, are the most frequently used instruments.</p><p><strong>Objectives: </strong>Primary: to determine the diagnostic accuracy of GAD-7 and GAD-2 to detect generalised anxiety disorder (GAD) and any anxiety disorder (AAD) in adults. Secondary: to investigate whether their diagnostic accuracy varies by setting, anxiety disorder prevalence, reference standard, and risk of bias; to compare the diagnostic accuracy of GAD-7 and GAD-2; to investigate how diagnostic performance changes with the test threshold.</p><p><strong>Search methods: </strong>We searched MEDLINE, Embase, PubMed-not-MEDLINE subset, and PsycINFO from 1990 to 18 January 2024. We checked reference lists of included studies and review articles.</p><p><strong>Selection criteria: </strong>We included cross-sectional studies conducted in adults, containing diagnostic accuracy information on GAD-7 and/or GAD-2 questionnaires for the target conditions generalised anxiety disorder and/or any anxiety disorder, and allowing the generation of 2x2 tables. The target conditions must have been diagnosed using a structured or semi-structured clinical interview. We excluded case-control studies and studies in which the time elapsed between the index tests and reference standards exceeded four weeks. We excluded studies involving people (1) seeking help in mental health settings or (2) recruited specifically due to mental health symptoms in other settings.</p><p><strong>Data collection and analysis: </strong>At least two review authors independently decided on study eligibility, extracted data, and assessed the risk of bias and applicability of included studies. For each questionnaire and each target condition, we present sensitivity and specificity with 95% confidence intervals (95% CI) in forest plots. We used the bivariate model to obtain summary estimates based on cut-offs closest to the recommended values (i.e. within a core range). In secondary analyses, we used the bivariate model and the multiple thresholds model to obtain summary estimates for all available cut-off points. Using the multiple thresholds model, we also calculated the area under the receiver operating characteristic curve to obtain a general indicator of the diagnostic accuracy of GAD-7 and GAD-2.</p><p><strong>Main results: </strong>We included 48 studies with 19,228 participants from 27 different countries, evaluating the GAD-7 and the GAD-2 in 24 different languages. Seven studies were performed in non-clinical settings, nine in clinical settings recruiting participants across conditions, and 32 in clinical settings with participants having specific conditions. Even after categorisation into three settings, the study populations were substantially different. The most frequently studied populations were people: with epilepsy (nine studies); with cancer (five studies); with cardiovascular disease (five studies); and in primary care regardless of their condition (five studies). We considered the risk of bias low in eight studies, and we had low concerns about the applicability of findings in three studies. Thirty-five studies contributed to the primary analyses of GAD-7 for detecting generalised anxiety disorder (median prevalence 12%); 22 studies to analyses of GAD-7 for any anxiety disorder (median prevalence 19%); 24 studies to analyses of GAD-2 for generalised anxiety disorder (median prevalence 9%); and 19 studies to analyses of GAD-2 for any anxiety disorder (median prevalence 19%). At the recommended cut-off of 10 or higher (or the closest available cut-off), the GAD-7 questionnaire yielded a summary sensitivity of 0.64 (95% CI 0.56 to 0.72) and a summary specificity of 0.91 (95% CI 0.87 to 0.93) in detecting generalised anxiety disorder. For detecting any anxiety disorder, summary sensitivity was 0.48 (95% CI 0.40 to 0.57) and summary specificity 0.91 (95% CI 0.89 to 0.93). At the recommended cut-off of 3 or higher (or the closest available cut-off), the GAD-2 yielded a summary sensitivity of 0.68 (95% CI 0.59 to 0.75) and a summary specificity of 0.86 (95% CI 0.82 to 0.89) for detecting generalised anxiety disorder. For detecting any anxiety disorder, the summary sensitivity was 0.53 (95% CI 0.44 to 0.62) and the summary specificity was 0.89 (95% CI 0.86 to 0.91). The 95% prediction region of GAD-7 for detecting generalised anxiety disorder was larger (indicating pronounced statistical heterogeneity) than for the three other analyses. Specificity varied by setting in the analysis of GAD-7 and GAD-2 for detecting any anxiety disorder, and by reference standard in the analysis of GAD-2 for detecting generalised anxiety disorder. Sensitivity varied with prevalence in the analysis of GAD-7 for generalised anxiety disorder. Other investigations of potential sources of heterogeneity did not show statistically significant associations with test accuracy. In all analyses, sensitivity tended to be higher and specificity lower in participants with specific conditions compared to the other two settings. Overall, the heterogeneity in the subgroup analyses remained high. The area under the receiver operating characteristic curve in the multiple thresholds model was 0.86 (95% CI 0.84 to 0.88) for the GAD-7 scale in detecting generalised anxiety disorder, and 0.80 (95% CI 0.78 to 0.82) in detecting any anxiety disorders. For the GAD-2 scale, the value was 0.82 (95% CI 0.81 to 0.86) for detecting generalised anxiety disorder, and 0.77 (95% CI 0.76 to 0.82) for detecting any anxiety disorders. Comparative bivariate analyses revealed no statistically significant differences between the diagnostic test accuracy of GAD-7 and GAD-2.</p><p><strong>Authors' conclusions: </strong>The GAD-7 and the GAD-2 scales have been tested in numerous languages and different populations. Overall, the GAD-7 and the GAD-2 seem to have acceptable or good diagnostic accuracy for both generalised anxiety disorder and any anxiety disorder. The GAD-2 scale seems to have similar diagnostic accuracy as the GAD-7 scale. However, due to the diversity of the included studies and the heterogeneity of our findings, our summary estimates of sensitivity and specificity should be interpreted as rough averages. The performance of GAD-7 and GAD-2 may deviate substantially from these values in specific situations.</p>","PeriodicalId":10473,"journal":{"name":"Cochrane Database of Systematic Reviews","volume":"3 ","pages":"CD015455"},"PeriodicalIF":8.8000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934853/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cochrane Database of Systematic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/14651858.CD015455","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Anxiety disorders often remain undetected and can cause substantial burden. Amongst the many anxiety screening tools, the 7-item Generalized Anxiety Disorder (GAD-7) scale and its short version, the 2-item Generalized Anxiety Disorder (GAD-2) scale, are the most frequently used instruments.

Objectives: Primary: to determine the diagnostic accuracy of GAD-7 and GAD-2 to detect generalised anxiety disorder (GAD) and any anxiety disorder (AAD) in adults. Secondary: to investigate whether their diagnostic accuracy varies by setting, anxiety disorder prevalence, reference standard, and risk of bias; to compare the diagnostic accuracy of GAD-7 and GAD-2; to investigate how diagnostic performance changes with the test threshold.

Search methods: We searched MEDLINE, Embase, PubMed-not-MEDLINE subset, and PsycINFO from 1990 to 18 January 2024. We checked reference lists of included studies and review articles.

Selection criteria: We included cross-sectional studies conducted in adults, containing diagnostic accuracy information on GAD-7 and/or GAD-2 questionnaires for the target conditions generalised anxiety disorder and/or any anxiety disorder, and allowing the generation of 2x2 tables. The target conditions must have been diagnosed using a structured or semi-structured clinical interview. We excluded case-control studies and studies in which the time elapsed between the index tests and reference standards exceeded four weeks. We excluded studies involving people (1) seeking help in mental health settings or (2) recruited specifically due to mental health symptoms in other settings.

Data collection and analysis: At least two review authors independently decided on study eligibility, extracted data, and assessed the risk of bias and applicability of included studies. For each questionnaire and each target condition, we present sensitivity and specificity with 95% confidence intervals (95% CI) in forest plots. We used the bivariate model to obtain summary estimates based on cut-offs closest to the recommended values (i.e. within a core range). In secondary analyses, we used the bivariate model and the multiple thresholds model to obtain summary estimates for all available cut-off points. Using the multiple thresholds model, we also calculated the area under the receiver operating characteristic curve to obtain a general indicator of the diagnostic accuracy of GAD-7 and GAD-2.

Main results: We included 48 studies with 19,228 participants from 27 different countries, evaluating the GAD-7 and the GAD-2 in 24 different languages. Seven studies were performed in non-clinical settings, nine in clinical settings recruiting participants across conditions, and 32 in clinical settings with participants having specific conditions. Even after categorisation into three settings, the study populations were substantially different. The most frequently studied populations were people: with epilepsy (nine studies); with cancer (five studies); with cardiovascular disease (five studies); and in primary care regardless of their condition (five studies). We considered the risk of bias low in eight studies, and we had low concerns about the applicability of findings in three studies. Thirty-five studies contributed to the primary analyses of GAD-7 for detecting generalised anxiety disorder (median prevalence 12%); 22 studies to analyses of GAD-7 for any anxiety disorder (median prevalence 19%); 24 studies to analyses of GAD-2 for generalised anxiety disorder (median prevalence 9%); and 19 studies to analyses of GAD-2 for any anxiety disorder (median prevalence 19%). At the recommended cut-off of 10 or higher (or the closest available cut-off), the GAD-7 questionnaire yielded a summary sensitivity of 0.64 (95% CI 0.56 to 0.72) and a summary specificity of 0.91 (95% CI 0.87 to 0.93) in detecting generalised anxiety disorder. For detecting any anxiety disorder, summary sensitivity was 0.48 (95% CI 0.40 to 0.57) and summary specificity 0.91 (95% CI 0.89 to 0.93). At the recommended cut-off of 3 or higher (or the closest available cut-off), the GAD-2 yielded a summary sensitivity of 0.68 (95% CI 0.59 to 0.75) and a summary specificity of 0.86 (95% CI 0.82 to 0.89) for detecting generalised anxiety disorder. For detecting any anxiety disorder, the summary sensitivity was 0.53 (95% CI 0.44 to 0.62) and the summary specificity was 0.89 (95% CI 0.86 to 0.91). The 95% prediction region of GAD-7 for detecting generalised anxiety disorder was larger (indicating pronounced statistical heterogeneity) than for the three other analyses. Specificity varied by setting in the analysis of GAD-7 and GAD-2 for detecting any anxiety disorder, and by reference standard in the analysis of GAD-2 for detecting generalised anxiety disorder. Sensitivity varied with prevalence in the analysis of GAD-7 for generalised anxiety disorder. Other investigations of potential sources of heterogeneity did not show statistically significant associations with test accuracy. In all analyses, sensitivity tended to be higher and specificity lower in participants with specific conditions compared to the other two settings. Overall, the heterogeneity in the subgroup analyses remained high. The area under the receiver operating characteristic curve in the multiple thresholds model was 0.86 (95% CI 0.84 to 0.88) for the GAD-7 scale in detecting generalised anxiety disorder, and 0.80 (95% CI 0.78 to 0.82) in detecting any anxiety disorders. For the GAD-2 scale, the value was 0.82 (95% CI 0.81 to 0.86) for detecting generalised anxiety disorder, and 0.77 (95% CI 0.76 to 0.82) for detecting any anxiety disorders. Comparative bivariate analyses revealed no statistically significant differences between the diagnostic test accuracy of GAD-7 and GAD-2.

Authors' conclusions: The GAD-7 and the GAD-2 scales have been tested in numerous languages and different populations. Overall, the GAD-7 and the GAD-2 seem to have acceptable or good diagnostic accuracy for both generalised anxiety disorder and any anxiety disorder. The GAD-2 scale seems to have similar diagnostic accuracy as the GAD-7 scale. However, due to the diversity of the included studies and the heterogeneity of our findings, our summary estimates of sensitivity and specificity should be interpreted as rough averages. The performance of GAD-7 and GAD-2 may deviate substantially from these values in specific situations.

广泛性焦虑障碍7项量表(GAD-7)和2项量表(GAD-2)用于检测成人焦虑障碍。
背景:焦虑症往往未被发现,并可能造成巨大负担。在许多焦虑筛查工具中,7项广泛性焦虑障碍(GAD-7)量表及其简短版本,2项广泛性焦虑障碍(GAD-2)量表是最常用的工具。目的:主要:确定GAD-7和GAD-2对成人广泛性焦虑症(GAD)和任何焦虑症(AAD)的诊断准确性。其次:调查其诊断准确性是否因环境、焦虑障碍患病率、参考标准和偏倚风险而异;比较GAD-7和GAD-2的诊断准确性;研究诊断性能如何随测试阈值变化。检索方法:检索1990年至2024年1月18日的MEDLINE、Embase、PubMed-not-MEDLINE子集和PsycINFO。我们检查了纳入研究和综述文章的参考文献列表。选择标准:我们纳入了在成人中进行的横断面研究,包含针对目标疾病广泛性焦虑症和/或任何焦虑症的GAD-7和/或GAD-2问卷的诊断准确性信息,并允许生成2x2表格。目标条件必须通过结构化或半结构化的临床访谈进行诊断。我们排除了病例对照研究和指标试验与参考标准之间的时间超过四周的研究。我们排除了涉及以下人群的研究:(1)在心理健康机构寻求帮助或(2)在其他环境中因心理健康症状而专门招募的人群。数据收集和分析:至少两名综述作者独立决定研究资格,提取数据,评估纳入研究的偏倚风险和适用性。对于每个问卷和每个目标条件,我们在森林样地中给出了95%置信区间(95% CI)的敏感性和特异性。我们使用双变量模型来获得基于最接近推荐值(即在核心范围内)的截止值的汇总估计。在二次分析中,我们使用双变量模型和多阈值模型来获得所有可用截止点的汇总估计。采用多阈值模型,我们还计算了受者工作特征曲线下的面积,以获得GAD-7和GAD-2诊断准确性的一般指标。主要结果:我们纳入了来自27个不同国家的48项研究,19228名参与者,用24种不同的语言评估了GAD-7和GAD-2。7项研究在非临床环境中进行,9项在临床环境中招募不同条件的参与者,32项在临床环境中招募有特定条件的参与者。即使将研究对象分为三种情况,研究人群也有很大的不同。研究最频繁的人群是:癫痫患者(9项研究);癌症(5项研究);患有心血管疾病(5项研究);在初级保健中,不管他们的状况如何(五项研究)。我们认为8项研究的偏倚风险较低,3项研究的结果的适用性较低。35项研究对用于检测广泛性焦虑症的GAD-7进行了初步分析(中位患病率为12%);22项研究分析了任何焦虑症的GAD-7(中位患病率19%);24项研究分析GAD-2治疗广泛性焦虑症(中位患病率9%);19项研究分析了GAD-2对任何焦虑症的影响(中位患病率19%)。在推荐的截止值为10或更高(或最接近的截止值)时,GAD-7问卷在检测广泛性焦虑症方面的总灵敏度为0.64 (95% CI 0.56至0.72),总特异性为0.91 (95% CI 0.87至0.93)。对于检测任何焦虑症,总敏感性为0.48 (95% CI 0.40至0.57),总特异性为0.91 (95% CI 0.89至0.93)。在推荐的截止值为3或更高(或最接近的截止值)时,GAD-2检测广泛性焦虑症的总灵敏度为0.68 (95% CI 0.59至0.75),总特异性为0.86 (95% CI 0.82至0.89)。对于检测任何焦虑症,总敏感性为0.53 (95% CI 0.44至0.62),总特异性为0.89 (95% CI 0.86至0.91)。GAD-7检测广泛性焦虑障碍的95%预测区域比其他三种分析更大(表明明显的统计异质性)。在分析检测任何焦虑症的GAD-7和GAD-2时,特异性因设置而异,在分析检测广泛性焦虑症的GAD-2时,特异性因参考标准而异。在分析GAD-7对广泛性焦虑障碍的影响时,敏感性随患病率而变化。 其他对异质性潜在来源的调查没有显示出与测试准确性有统计学意义的关联。在所有分析中,与其他两种情况相比,具有特定条件的参与者的敏感性往往更高,特异性则更低。总的来说,亚组分析的异质性仍然很高。在多阈值模型中,GAD-7量表检测广泛性焦虑症的受试者工作特征曲线下面积为0.86 (95% CI 0.84 ~ 0.88),检测任何焦虑症的受试者工作特征曲线下面积为0.80 (95% CI 0.78 ~ 0.82)。对于GAD-2量表,检测广泛性焦虑症的值为0.82 (95% CI 0.81至0.86),检测任何焦虑症的值为0.77 (95% CI 0.76至0.82)。比较双变量分析显示,GAD-7和GAD-2的诊断准确性无统计学差异。作者的结论是:GAD-7和GAD-2量表已经在许多语言和不同的人群中进行了测试。总的来说,GAD-7和GAD-2似乎对广泛性焦虑症和任何焦虑症都有可接受或良好的诊断准确性。GAD-2量表似乎与GAD-7量表具有相似的诊断准确性。然而,由于纳入研究的多样性和我们研究结果的异质性,我们对敏感性和特异性的总结估计应被解释为粗略的平均值。在特定情况下,GAD-7和GAD-2的性能可能会大大偏离这些值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.60
自引率
2.40%
发文量
173
审稿时长
1-2 weeks
期刊介绍: The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信